Advanced mtDNA Point Mutations and Deletions by Massively Parallel Sequencing

Clinical Use

Use

Advanced mtDNA Point Mutations and Deletions analyzes 36 point mutations in 17 mitochondrial genes using Massively Parallel Sequencing (MPS) technology. This test is vital for detecting mtDNA mutations in at least 85% of patients with primary mtDNA defects. It can identify heteroplasmic point mutations with a minimum detection threshold of 1.5%. Significant mutations have been linked to various mitochondrial disorders, including chronic progressive external ophthalmoplegia, Kearns-Sayre syndrome, and Leigh syndrome. These mutations underline the importance of timely genetic analysis for patients presenting symptoms of mitochondrial disorders, thereby providing essential information for diagnosis and management.

Special Instructions

Sample collection requires specific methods depending on the specimen type. Blood should be drawn in EDTA tubes, and DNA samples must be at least 5ug. It is essential to follow shipping instructions carefully to maintain specimen integrity. Patients should avoid heat or freezing during transport. Certain specimens may have extended turnaround times if additional culture is needed.

Limitations

While this assay can correctly identify large deletions and multiple deletions, it may not reliably determine the heteroplasmy levels present in such rearrangements. The amplification process may exhibit preferential bias towards smaller molecules, leading to challenges in accurately assessing heteroplasmic levels. Additionally, limits in detection may exist for certain rare mutations, necessitating cautious interpretation of results. The broader implications of findings should be considered in conjunction with clinical assessments and patient histories.

Test Details